Skip to main content
Clinical Trials/NCT07272239
NCT07272239
Recruiting
Not Applicable

Combined Effects of Transcutaneous Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Upper Extremity Function, Cognition and Quality of Life in Individual With Chronic Stroke

Riphah International University2 sites in 1 country50 target enrollmentStarted: November 25, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
50
Locations
2
Primary Endpoint
Nine- hole peg test (NHPT)

Overview

Brief Summary

Stroke is a leading cause of death and disability worldwide, resulting in significant physical and cognitive impairments. Arm weakness is most common after stroke and its treatment is recognized as an area of considerable need. The functional limitations and disabilities experienced by stroke survivors, particularly in the upper limb have a profound impact on their quality of life. Current treatment for arm weakness typically comprises intensive, task-specific and repetitive rehabilitative interventions. Transcutaneous auricular vagus nerve stimulation (tVNS) is a novel noninvasive treatment for stroke that directly stimulates the peripheral auricular branch of the vagus nerve. This study determines the effects of Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Motor Function, Cognition, and Quality of life in chronic stroke patients.

This randomized clinical trial will be conducted at IIMCT Railway General Hospital and Al-firdous physiotherapy clinic over a duration of six months. The sample size will consist of 50 participants. Participants which meet the inclusion criteria will be taken through non-probability convenience sampling technique, which will further be randomized through online randomization tool. 25 Participants will be assigned to Group A receiving tVNS and mCIMT with routine physical therapy and 25 to Group B receiving mCIMT with routine physical therapy . Data will be collected using various assessment tools, including Fugl-Meyer Assessment-UE (FM-UE), and Nine-hole peg test (NHPT) to assess Motor function. Stroke Impact Scale (SIS) to assess QOL, Montreal cognitive assessment (MoCA) to assess cognition, and Modified Ashworth scale to assess spasticity. All participants will receive intervention 3 days a week on alternative days for 8 weeks. Pre-intervention assessments will be conducted for both groups. The effects of the interventions will be measured at pre-treatment, 4th week, and post-intervention. Data analysis will be performed by using SPSS 26 software.

Key words: Modified Constraint Induced movement Therapy, Motor function, Rehabilitation, Stroke, Transcutaneous Vagus nerve stimulation, Upper extremity.

Detailed Description

Stroke is the third leading cause of death and the leading cause of adult disability. Patients with stroke suffer from neuromuscular disabilities, including impairments in motor control. Stroke survivors with hemiplegia exhibit more upper-limb (UL) than lower-limb (LL) disability. Dysfunction from upper extremity hemi paresis impairs performance of many daily activities such as dressing, bathing, self-care and writing, thus reducing functional independence. Only 5% of adults regain full arm function after stroke, and 20% regain no functional use. Restoration of full function to the stroke affected upper extremity is a major problem in rehabilitation. Hence alternative strategies are needed to reduce the long-term disabilities and functional impairment resulting from upper extremity hemi paresis.

The severity of the neurological deficits and early patterns of improvement are the two best predictors of recovery from impairments. Patients are generally thought to experience less UL motor recovery than LL motor recovery; however, this clinical belief is typically based on disability assessments rather than tests of specific motor deficits of UL and LL. Since UL function needs finer motor control than LL function, this might explain the common scenario of less variation between impairment and disability. There are several promising treatment options available for upper-limb stroke rehabilitation, such as cross education, constraint-induced movement therapy, virtual reality therapy, functional electrical stimulation, robotic therapy, anodal transcranial direct current stimulation, and motor imagery.

Unfortunately, VNS necessitates a costly, invasive surgical procedure. In the last years, transcutaneous VNS (ta-VNS) has been proposed as a noninvasive and patient friendly method to stimulate the vagus nerve, through the skin, by delivering weak electric current to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. Such stimulation activates the auricular branch of the vagus nerve and, via this pathway, the nuclei of the nerve located in the brainstem, enhancing brain GABA and Noradrenaline levels, which plays a pivotal role in brain plasticity. These connections regulate the release of neuromodulators, including acetylcholine, norepinephrine, serotonin, and brain-derived neurotrophic factors, which promote cortical plasticity.

The rationale for this study lies in its potential to uncover synergistic benefits from combining these two therapies, ultimately aiming to enhance functional recovery and cognitive engagement among chronic stroke survivors, thereby improving their daily lives and reintegration into society. The exploration of effective rehabilitation strategies is crucial, as traditional therapies frequently provide limited benefits for chronic stroke patients, particularly concerning upper extremity function. This research investigates the combined effects of ta-VNS and Modified CIMT on these patients, aiming to enhance motor recovery and cognitive engagement. The findings may inform future therapeutic approaches and offer hope for improved independence and well-being among individuals affected by chronic stroke.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
50 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Both male and female patients are included in the study.
  • Left sided ischemic stroke patients.
  • Patients with chronic, moderate-severe upper limb hemiparesis (\>6 months-2 years)
  • Stable participants having a stroke severity score \> 6 on National Institute of Health Stroke Scale (NIHSS).
  • Montreal Cognitive Assessment (MoCA) score ≥26.

Exclusion Criteria

  • Participants who show the symptoms of global or receptive aphasia.
  • Participants who have a history of significant neurological or psychiatric disorders, other than stroke, that could interfere with upper limb motor or sensory recovery.
  • Modified Ashworth scale score ≥ 3 of the affected upper extremity.
  • Patients who are not able to sit with or without support.
  • Patients with severe apraxia, somatosensory problems.
  • Resting heart rate (\< 50 beats/min).
  • Participants who are currently participating in another clinical trial or research study.

Outcomes

Primary Outcomes

Nine- hole peg test (NHPT)

Time Frame: Assessment will be done at baseline, 4th and 8th week of intervention

The Nine-Hole Peg Test (NHPT) is a widely used assessment tool for measuring manual dexterity and fine motor skills, particularly in clinical populations such as stroke and multiple sclerosis patients. The test involves placing and removing nine pegs from a pegboard as quickly as possible, with the time taken recorded in seconds. Reliability is strong, with intraclass correlation coefficients (ICCs) ranging from 0.91 to 0.94 for individuals with stroke and 0.49 to 0.66 for healthy adults, indicating good relative reliability. Validity is supported by its ability to discriminate between varying levels of impairment and its correlation with other dexterity measures, confirming its effectiveness in clinical settings.

Montreal cognitive assessment (MoCA)

Time Frame: Assessment will be done at baseline, 4th and 8th week of intervention

The Montreal Cognitive Assessment (MoCA) is a widely utilized screening tool developed by Dr. Ziad Nasreddine in 1996 to detect cognitive impairment, particularly mild cognitive impairment (MCI) and early Alzheimer's disease. The test takes about 10 minutes and evaluates multiple cognitive domains, including memory, attention, language, executive function, and visuospatial abilities. MoCA has shown high reliability (ICC = 0.92) and good internal consistency (Cronbach's alpha = 0.82). Its sensitivity for detecting MCI is 90%, with a specificity of 87% compared to the Mini-Mental State Examination (MMSE).

Fugl- Meyer Assessment- UE (FM-UE)

Time Frame: Assessment will be done at baseline, 4th and 8th week of intervention

The Fugl-Meyer Assessment of Upper Extremity (FMA-UE) is a reliable and valid tool for evaluating upper limb function in stroke patients. Comprising 33 items, it assesses motor function, sensory function, and joint mobility. The FMA-UE demonstrates excellent intra-rater (ICC \> 0.90) and inter-rater reliability (median agreement \~77%). It correlates well with other measures, showing strong construct validity and responsiveness, making it essential for tracking recovery in rehabilitation settings.

Stroke impact scale (SIS)

Time Frame: Assessment will be done at baseline, 4th and 8th week of intervention

The Stroke Impact Scale (SIS) is a patient-reported outcome measure designed to evaluate the effects of stroke on various aspects of life, including physical, emotional, and social domains. Developed by Duncan et al. in 1999, the SIS assesses eight dimensions: strength, hand function, mobility, activities of daily living, emotion, memory, communication, and social participation. The scale produces scores ranging from 0 to 100, with higher scores indicating better function. It has demonstrated excellent reliability (Cronbach's alpha = 0.83 to 0.95) and validity in predicting quality of life post-stroke.

Secondary Outcomes

  • Modified Ashworth Scale (MAS)(Assessment will be done at baseline, 4th and 8th week of intervention)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials